Browse SGMS2

Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Golgi apparatus membrane; Multi-pass membrane protein. Note=Predominantly plasma membrane, some in Golgi apparatus. Some localization in the perinuclear region where it colocalizes with a sialyltransferase.
Domain PF14360 PAP2 superfamily C-terminal
Function

Sphingomyelin synthases synthesize the sphingolipid, sphingomyelin, through transfer of the phosphatidyl head group, phosphatidylcholine, on to the primary hydroxyl of ceramide. The reaction is bidirectional depending on the respective levels of the sphingolipid and ceramide. Plasma membrane SMS2 can also convert phosphatidylethanolamine (PE) to ceramide phosphatidylethanolamine (CPE). Major form in liver. Required for cell growth in certain cell types. Regulator of cell surface levels of ceramide, an important mediator of signal transduction and apoptosis. Regulation of sphingomyelin (SM) levels at the cell surface affects insulin sensitivity.

> Gene Ontology
 
Biological Process GO:0006643 membrane lipid metabolic process
GO:0006644 phospholipid metabolic process
GO:0006665 sphingolipid metabolic process
GO:0006672 ceramide metabolic process
GO:0006684 sphingomyelin metabolic process
GO:0006686 sphingomyelin biosynthetic process
GO:0008654 phospholipid biosynthetic process
GO:0030148 sphingolipid biosynthetic process
GO:0046467 membrane lipid biosynthetic process
GO:0046513 ceramide biosynthetic process
GO:0097164 ammonium ion metabolic process
Molecular Function GO:0016780 phosphotransferase activity, for other substituted phosphate groups
GO:0033188 sphingomyelin synthase activity
GO:0047493 ceramide cholinephosphotransferase activity
Cellular Component GO:0030173 integral component of Golgi membrane
GO:0030176 integral component of endoplasmic reticulum membrane
GO:0031227 intrinsic component of endoplasmic reticulum membrane
GO:0031228 intrinsic component of Golgi membrane
GO:0031300 intrinsic component of organelle membrane
GO:0031301 integral component of organelle membrane
> KEGG and Reactome Pathway
 
KEGG hsa04071 Sphingolipid signaling pathway
hsa00600 Sphingolipid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-1660661: Sphingolipid de novo biosynthesis
R-HSA-428157: Sphingolipid metabolism
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SGMS2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SGMS2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen Total # shRNA with >= 4-fold: 1 Resistant to T-cell proliferation
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SGMS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0510.889
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3760.674
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2010.712
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3040.453
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0820.954
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.590.76
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1910.674
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0560.964
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.3510.801
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.4460.669
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8740.574
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0570.706
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SGMS2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.72.711
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.73.40.31
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.63.7-1.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SGMS2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SGMS2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SGMS2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SGMS2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SGMS2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SGMS2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSGMS2
Namesphingomyelin synthase 2
Aliases MGC26963; SMS2; SM synthase; Phosphatidylcholine:ceramide cholinephosphotransferase 2
Chromosomal Location4q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SGMS2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.